{
  "id": 17770376,
  "title": "1 Reason Compass Pathways Is Worth a Second Look This Month",
  "url": "https://urgent.news/2026/11/02/1-reason-compass-pathways-is-worth-a-second-look-this-month",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T08:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/02/1-reason-compass-pathways-is-worth-a-second-look/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Compass Pathways, a company developing a synthetic version of psilocybin for treating treatment-resistant depression, is on the verge of potentially receiving FDA approval for its treatment, COMP360. Recent positive results from two Phase 3 trials have bolstered investor confidence, and the FDA has granted COMP360 a Commissioner's National Priority Voucher, which could expedite the review process. If approved, COMP360 could offer lasting relief with fewer treatments compared to conventional antidepressants. Analysts have set high expectations for the stock, with an average price target of $23.75, representing approximately 95% upside from its current trading price around $12. While approval is not guaranteed, the accelerated regulatory pathway and strong Phase 3 trial results suggest a potential significant boost in stock value for investors who buy now.",
  "summary": "An accelerated FDA review could benefit Compass Pathways.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "1 Reason Compass Pathways Is Worth a Second Look This Month",
        "url": "https://urgent.news/2026/11/02/1-reason-compass-pathways-is-worth-a-second-look-this-month-17771359",
        "published": "2026-11-02T08:50:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}